Report copyright - AOMI Nouveaux traitements en 2019 · Dual Pathway Inhibition with Rivaroxaban 2.5 mg bid + Aspirin Significantly Reduced MACE by 28% and MALE by 46% Versus Aspirin Outcome Rivaroxaban
Please pass captcha verification before submit form